AIM Ketogenic diet therapies have proven efficacy for refractory epilepsy. There are many reports of their use in the genetic developmental and epileptic encephalopathies; however, little attention has been paid as to whether the diet is also effective in individuals with an acquired structural aetiology. We observed remarkable efficacy of the diet in two patients with hypoxic-ischaemic encephalopathy. We then analysed our cases with refractory structural epilepsies of acquired origin to characterize their response to the ketogenic diet.
Patients with severe epilepsy secondary to an acquired structural aetiology may have refractory seizures that are not surgically amenable, often in association with bilateral cortical involvement. Patients with structural brain lesions acquired in infancy, such as hypoxic-ischemic encephalopathy, intraventricular haemorrhage, infections, or birth trauma, are at high risk of developing refractory epilepsy. 1 In these patients, the management of refractory epilepsy remains extremely challenging despite the availability of multiple antiepileptic drugs.
The ketogenic diet has been used in the treatment of refractory childhood epilepsy since the 1920s. It is a medically initiated high fat, low carbohydrate diet with demonstrated efficacy in many epilepsy syndromes, including epilepsy with myoclonic-atonic seizures (described by Doose), Lennox-Gastaut syndrome, and Dravet syndrome. 2, 3 The ketogenic diet is also the treatment of choice for two rare disorders of brain energy metabolism: glucose transporter 1 deficiency and pyruvate dehydrogenase deficiency. 4, 5 Most studies of ketogenic diet efficacy have focused on seizure types or epilepsy syndromes rather than specific aetiological subgroups. Two patients with hypoxic-ischemic encephalopathy from our study of 61 patients on the ketogenic diet were seizure-free at 6 months. 6 This led to the hypothesis that patients with refractory epilepsy associated with an acquired structural encephalopathy may respond to the ketogenic diet. Here, we analysed the responder rate in a collaborative cohort of patients with refractory epilepsy associated with an acquired structural epileptic encephalopathy.
METHOD
In this retrospective study, patients were referred to the ketogenic diet clinics at Austin Health, Melbourne, Australia (IES) and Great Ormond Street Hospital for Children, London, UK (JHC). Children with a history of acquired neonatal or infantile structural lesions who developed refractory epilepsy were included. Refractory epilepsy was defined as failure to achieve seizure freedom after adequate trials of two or more suitable antiepileptic medications. 7 A developmental and epileptic encephalopathy was diagnosed by a paediatric neurologist on the basis of developmental impairment and frequent epileptic activity on electroencephalogram that was associated with slowing of development beyond that expected from the structural lesion alone. 8, 9 Patients underwent detailed clinical history and physical examination before initiating the diet. Diagnostic tests were performed for metabolic and renal conditions that would preclude patients from starting the ketogenic diet. Electroencephalogram and magnetic resonance imaging brain studies were analysed. Seizures were classified and an epilepsy syndrome diagnosis made according to the 2010 International League Against Epilepsy classification. 8 The ketogenic diet was initiated using a modified Johns Hopkins protocol. A fat to carbohydrate and protein ratio of 3:1 to 4.4:1 was used to achieve the necessary level of ketosis. The dietary ratio, energy, and protein intake were adjusted to achieve desired ketone levels and maintain appropriate growth with minimal side effects. Urinary ketones were monitored twice daily with the goal of 8mmol/L in the morning and 16mmol/L at night. For patients younger than 5 years, blood ketone levels between 2.4mmol/L and 4.2mmol/L were sometimes used. Doses of concurrent antiepileptic drugs were kept stable during the first 3 months of the diet at least.
Seizure diaries were completed for a 28-day period before commencement (baseline seizure frequency) and on the ketogenic diet. The average daily seizure frequency was calculated for the 28-day period before each time point and compared to the average baseline daily seizure frequency. The primary outcome was the percentage change in seizure frequency at 1 month, 3 months, 6 months, 1 year, and 2 years (when data was available) compared to baseline. A responder was defined as a patient who achieved greater than 50% reduction in seizure frequency.
This study was approved by the Austin Health Human Research Ethics Committee.
RESULTS
Nine patients with an acquired structural developmental and epileptic encephalopathy were recruited to the study (Table I ). All nine patients were diagnosed with hypoxicischemic encephalopathy, intraventricular haemorrhage, or perinatal brain injury in the neonatal or infantile period. All consecutive patients with acquired structural brain injury included in the ketogenic diet programs of Austin Health and the Great Ormond Street Hospital for Sick Children between 2001 and 2010 were included. The clinical, electroencephalogram, and imaging findings are described in Table I . Median seizure onset was 12 months (range: 1mo-4y). All patients had multiple seizure types with daily frequencies ranging from five to innumerable seizures. Intellectual disability was profound in seven patients and moderate in two. All patients had cerebral palsy; seven had spastic quadriplegia, one had spastic diplegia, and one had hemiplegia. Neuroimaging showed variable degrees of brain injury including widespread cortical damage, white matter gliosis, and periventricular leukomalacia.
Three months after ketogenic diet initiation, seven out of nine patients were responders and all patients showed some improvement. At 6 months postinitiation, six out of seven patients who remained on the diet were responders. Three patients were seizure-free, and two had reductions greater than 94%. After 1 year, six out of six patients on the diet were responders with three seizure-free, and two had greater than 90% seizure reduction. After 2 years, all five patients remaining on the diet were responders including three seizure-free and two with 70% or 95% reduction.
Subjective improvements in cognition were documented even with minimal effect on seizure frequency or even when the patient later discontinued the diet. Families observed increased alertness, vocalization, improved behaviour, and subtle developmental gains in all children. The reason for discontinuing the ketogenic diet in four cases was that the child refused the diet. Three of the nine children had percutaneous endoscopic gastrostomies. No child was weaned because of side effects such as weight loss or renal calculi.
DISCUSSION
Acquired structural causes of encephalopathy have an increased risk of epilepsy and other neurological sequelae. Neonates with hypoxic-ischemic encephalopathy or meningitis have a risk of epilepsy of around 12%. 1 The seizure disorder is often refractory and may cause an epileptic encephalopathy that impacts on developmental progress beyond that caused by the structural pathology alone. To our knowledge, this is the first study to specifically focus on the effectiveness of the ketogenic diet in patients with acquired structural epileptic encephalopathy.
The ketogenic diet is a well-recognized and effective treatment for refractory childhood epilepsy. 2, 10 In particular, it is a highly effective treatment for genetic developmental and epileptic encephalopathies such as epilepsy with myoclonic-atonic seizures and Dravet syndrome. 11 In Dravet syndrome, responder rates of 65% are reported. 12, 13 In epilepsy with myoclonic-atonic seizures, 55% (6/11) of patients were observed to have greater than 50% seizure reduction at 18 months, with seizure freedom in 2 out of 11 patients. 14 We found a striking responder rate of 78%, although our sample size is small. This is not dissimilar to genetic structural epilepsies, such as tuberous sclerosis where, in one study, 11 out of 12 patients had a greater than 50% response rate. 15 Efficacy has also been established in malformations of cortical development. A Korean study found that 29 out of 47 patients were responders after 3 months on the diet. 16 What this paper adds
• The ketogenic diet was effective in children with epilepsy associated with an acquired structural aetiology. Lennox-Gastaut syndrome can occur in the setting of both genetic and acquired structural aetiologies; Lemmon et al. found that 6 out of 25 patients achieved greater than 90% seizure reduction. 3 Although some patients with lesional epilepsy are epilepsy surgery candidates, in many cases the abnormalities are too extensive to be surgically amenable. For such patients with devastating epilepsy, the ketogenic diet may be a worthwhile therapeutic option.
Here, seven out of nine patients with an acquired structural aetiology showed greater than 50% response at 3 months. At 2 years, five out of five patients who remained on the ketogenic diet were responders. If the patients who stopped the diet early are included, this is still a responder rate of five out of nine. This responder rate is considerably greater than that observed in our broader study of 61 patients with refractory epilepsy caused by genetic, structural, and unknown aetiologies who had an overall 2-year responder rate of data of 14%. 6 This suggests that patients with acquired structural aetiologies may be particularly responsive to the ketogenic diet. Studies with a larger sample size are required to confirm this positive response.
Interestingly, the families of our patients remarked on significant gains in development and quality of life. Most notably, alertness, calmness, and developmental progress were seen, as documented previously. 17 It is not known whether these behavioural effects are because of decreased seizure frequency or to the ketosis. Even our patients with a minimal change in seizure frequency experienced behavioural and developmental improvements, often continuing after dietary cessation. 18 While these parental observations are promising, we acknowledge that such reports are likely to be subject to bias. Responses are often noted in the placebo arm of placebo-controlled studies, and are even more prominent in paediatric than adult trials. 19 It would be ideal to have objective assessments of the cognitive and behavioural changes, although cognitive gains are likely to be very subtle in profoundly impaired patients.
At first glance, the attrition rate of patients on the ketogenic diet in our study may seem high, yet careful analysis suggests this is not the case. At 3 months, all of our children were still on the ketogenic diet which compares favourably with the attrition rate in our previous studies of 21% (13/61 ) and 26% (19/73). 6, 10 The remainder of the follow-up rates (6mo-2y) were similar to our previous study confirming that patients with acquired structural encephalopathy find the diet at least as efficacious as other groups. 6 In four patients, the ketogenic diet was stopped as the patient refused the diet. Given the efficacy of the ketogenic diet in this population, a gastrostomy may be worth considering if it renders the patient seizure-free and improves the quality of life for the patient and their family.
There has been extensive research into the multiple mechanisms underlying the efficacy of the ketogenic diet. 20 Recent interest has highlighted that the epigenetic machinery may be modified through metabolic intervention. 21 Experimental acquired epilepsy models have shown genome-wide changes in DNA methylation with aetiology-dependent epigenetic signatures. 22 Thus, the ketogenic diet may affect methylation patterns affecting gene expression, and thereby influence seizure susceptibility in individuals with acquired structural epilepsy. The increasing awareness of anti-inflammatory effects in antiepileptic therapies is also likely to be relevant to the efficacy of the ketogenic diet in patients with epilepsy associated with an acquired structural aetiology. 23 The ketogenic diet decreases proinflammatory cytokine levels after an immune challenge through multiple processes and molecular targets. These include an increase in polyunsaturated fatty acids, 24 which block epileptiform activity on in vivo and in vitro seizure models, as well as effects on mitochondrial function. 25 We report a series of refractory patients with acquired structural epileptic encephalopathy with impressive responses to the ketogenic diet. Additional benefits, such as increased alertness, improved motor development, and behaviour, were apparent. The role of the ketogenic diet early in the treatment algorithm of children with acquired neonatal and infantile cerebral injury should be considered. Earlier seizure control in this highly refractory population has the potential to improve prognosis and quality of life for the patient and their family.
